Rosetta Genomics Reports Rise in Q1 Revenues and Loss; Suspends Guidance | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics today reported a slight rise in its first-quarter revenues and a 6 percent increase in its net loss year over year.

The microRNA-based diagnostics firm reported total revenues of $27,000 for the three-month period ended March 31, compared to $17,000 for the first quarter of 2009.

Rosetta's net loss for the quarter was $3.6 million, or $.22 per share, compared to $3.4 million, or $.30 per share, for Q1 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.